ClinicalTrials.gg
RecruitingNCT04090034PRRTUpdated Mar 20, 2026

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

An observational study in Neuroendocrine Tumors and Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Methodist Health System. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Primary conditionGastro-enteropancreatic neuroendocrine tumorRegistry: Neuroendocrine TumorsReclassifiedWhy we changed it
Registry
Neuroendocrine Tumors — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gastro-enteropancreatic neuroendocrine tumor
Why
  1. The study's listed conditions name Gastro-enteropancreatic neuroendocrine tumor, a narrower term within Neuroendocrine Tumors.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Methodist Health System · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States — 7 open to participants now, 16 under way, 5 of them phase 3. Gastro-enteropancreatic neuroendocrine tumor · United States.

Started
2024
with 2 others
Observational
8 of 30
2 open now
Primary completion
2026-06
later than 4 of 15 live
Registered
12th of 30
by date

Among the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States, this one is one of 3 that started in 2024, is one of 8 observational ones, reaches primary completion later than 4 of the 15 other live ones, and was the 12th registered.

Gastro-enteropancreatic neuroendocrine tumor

73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.

Browse Gastro-enteropancreatic neuroendocrine tumor studies →

Open to participants now

7 of the 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Gastro-enteropancreatic neuroendocrine tumor studies recruiting now, 13 (62%) set no upper age limit and 4 (19%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Gastro-enteropancreatic neuroendocrine tumor with a site in United States, or all of them as a file.
02

Study summary

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Read the detailed description

Neuroendocrine tumors (NETs) make up a large range of malignancies that arise from neuroendocrine cells in multiple organs of the body. Hallet et al conducted a large population-based study that demonstrated that 21% of NET patients presented with metastatic disease and another 38% developed metastases after resection of the primary tumor (Hallet et al., 2015). This burden demonstrates the need for effective systemic therapy for advanced NETs. Options for systemic therapy include peptide receptor radionuclide therapy (PRRT).

A need for more prospective series are needed on treatment responses and survival outcomes related to gastroenteropancreatic primary NETs treated with PRRT was identified. Thus the purpose of this study is to collect clinical data related to treatment of gastroenteropancreatic primary NETs s with PRRT. Clinical data related to patient characteristics, treatment responses and survival outcomes related to the treatment of gastroenteropancreatic primary NETs with PRRT and on adverse events and complications related to PRRT treatment will be collected.

03

Conditions studied

  • Neuroendocrine Tumors
  • Gastroenteropancreatic Neuroendocrine Tumor

Browse trials for

04

In context

Gastro-enteropancreatic neuroendocrine tumor Reclassified

73 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 25 are open to participants now.

This study's planned enrollment of 50 is below the median of 164 across 21 observational studies indexed under Gastro-enteropancreatic neuroendocrine tumor.

Browse Gastro-enteropancreatic neuroendocrine tumor studies →

Lead sponsor

Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.

Compared within Gastro-enteropancreatic neuroendocrine tumor, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neuroendocrine Tumors. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients will be screened for NETs per standard of care. Those patients, who have or will undergo the PRRT procedure, will be offered the opportunity to participate in this registry study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. > 18 years of age
  2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:

    • Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
    • or Locally Advanced AND Inoperable
    • Clear disease progression on Octreotide over less than 3 years ( 1.1)
    • Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET
    • Well differentiated on path - Ki67 \< 20%
    • Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:

      • Cr. \<1.7
      • >8
      • WBC >2K
      • Plt >75K
      • Bili \< 3x normal limit
    • No Octreotide within 30 days of administration.
  3. Willing and able to comply with the protocol requirements
  4. Able to comprehend and sign the Form in English.

Exclusion criteria

Exclusion Criteria:

  • Do not meet the Study Inclusion Criteria laid out in section 6.3
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Treated w PRRT

    Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.

    Procedure: Peptide Receptor Radionuclide Therapy

Interventions

  • ProcedurePeptide Receptor Radionuclide Therapy

    a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs

07

What researchers measure

Primary outcomes

  1. Demographics and other patient data

    (such as age at diagnosis, sex, history of smoking alcohol use and symptoms at the time of diagnosis)

    Time frame: 7 years from date of procedure

  2. Tumor specific data

    Tumor site, tumor grade, stage, presence of tumor necrosis, number of mitoses and percentage of Ki-67 and MIB-1 positive cells (proliferative index)

    Time frame: 7 years from date of procedure

  3. Use of somatostatin analogs

    at the time of PRRT, location, isotope used and dose of isotope for each PRRT

    Time frame: 7 years from date of procedure

  4. Biomarker data (chromogranin A and pancreastatin)

    at the time of diagnosis, before and after the first PRRT, and after the second PRRT were also extracted

    Time frame: 7 years from date of procedure

  5. Diagnostic imaging findings

    prior to PRRT and response after PRRT, date of progression on imaging after PRRT, and status of disease on imaging at the last follow-up were also recorded

    Time frame: 7 years from date of procedure

  6. Overall survival (OS)

    the time from diagnosis to death of any cause.

    Time frame: 7 years from date of procedure

  7. Time to progression (TTP)

    the time from the first PRRT until any progression on diagnostic imaging

    Time frame: 7 years from date of procedure

  8. Treatment responses and progression

    assessed with cross-sectional imaging with either computerized tomography (CT) or magnetic resonance imaging (MRI) or positron emission tomography (PET) or single-photon emission computed tomography (SPECT).

    Time frame: 7 years from date of procedure

  9. Response

    any response of any magnitude

    Time frame: 7 years from date of procedure

  10. Disease progression

    any increase in lesion sizes and/or appearance of new metastatic lesions on diagnostic imaging exams.

    Time frame: 7 years from date of procedure

  11. Adverse events

    will be assessed by the investigator who will determine whether or not the event is related to PRRT or related to progression of disease (gastroenteropancreatic primary NET), and whether or not the event meets serious criteria. AEs related to PRRT will be recorded in the study registry.

    Time frame: 7 years from date of procedure

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jun 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2019
First posted
Sep 16, 2019
StartActual
Mar 28, 2024
Primary completionEst.
Jun 28, 2026
CompletionEst.
Jun 28, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04090034
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Mar 28, 2024
Primary completion
Jun 28, 2026 (estimated)
Completion
Jun 28, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Colette N Ndjom, MS
Contact
clinicalresearch@mhd.com
214-947-1280
Jennifer Kirchner
Contact
clinicalresearch@mhd.com
214-947-1280 ext. 74459
Alejandro Mejia, MD
principal investigator · Liver Institute at Methodist Dallas Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion